

Bernard H Bochner

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7586132/bernard-h-bochner-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

221
papers

19,013
citations

61
h-index

136
g-index

255
ext. papers

23,441
ext. citations

6.2
avg, IF

6.21
L-index

#	Paper	IF	Citations
221	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101485	2.2	2
220	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. <i>Cell</i> , 2022 , 185, 563-575.e11	56.2	11
219	Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort. <i>European Urology</i> , 2021 , 81, 294-294	10.2	3
218	Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 4599-4609	12.9	4
217	Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.07.016 . <i>European Urology</i> , 2021 ,	10.2	
216	Definition of a Structured Training Curriculum for Robot-assisted Radical Cystectomy with Intracorporeal Ileal Conduit in Male Patients: A Delphi Consensus Study Led by the ERUS Educational Board. <i>European Urology Focus</i> , 2021 ,	5.1	6
215	Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes Following Radical Cystectomy. <i>Journal of Urology</i> , 2021 , 205, 400-406	2.5	2
214	(-) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract.. <i>Bladder Cancer</i> , 2021 , 7, 395-400	1	1
213	Management of Common Complications After Radical Cystectomy, Lymph Node Dissection, and Urinary Diversion 2021 , 185-203		
212	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. <i>British Journal of Cancer</i> , 2021 , 124, 1214-1221	8.7	4
211	Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2020 , 3, 306-315	6.7	46
210	Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 387-394	3.3	14
209	Primary urethral cancer: treatment patterns and associated outcomes. <i>BJU International</i> , 2020 , 126, 359-366	3.66	2
208	Ileal conduit or orthotopic neobladder: selection and contemporary patterns of use. <i>Current Opinion in Urology</i> , 2020 , 30, 415-420	2.8	11
207	Reply by Authors. <i>Journal of Urology</i> , 2020 , 204, 684	2.5	
206	Reply by Authors. <i>Journal of Urology</i> , 2020 , 204, 259	2.5	
205	Goal-directed versus Standard Fluid Therapy to Decrease Ileus after Open Radical Cystectomy: A Prospective Randomized Controlled Trial. <i>Anesthesiology</i> , 2020 , 133, 293-303	4.3	11

204	Utility of Routine Preoperative F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. <i>Journal of Urology</i> , 2020 , 204, 254-259	2.5	13
203	Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations. <i>Journal of Urology</i> , 2020 , 204, 460-465	2.5	2
202	Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience. <i>Journal of Urology</i> , 2020 , 204, 677-684	2.5	9
201	A Population-based Study of Ureteroenteric Strictures After Open and Robot-assisted Radical Cystectomy. <i>Urology</i> , 2020 , 135, 57-65	1.6	16
200	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. <i>Journal of Clinical Oncology</i> , 2020 , 38, 406-414	2.2	31
199	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. <i>European Urology</i> , 2020 , 77, 223-250	10.2	60
198	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020 , 78, 907-915	10.2	9
197	Predictors of Benign Ureteroenteric Anastomotic Strictures After Radical Cystectomy and Urinary Diversion. <i>Urology</i> , 2020 , 144, 225-229	1.6	10
196	Lymph Node Dissection for Advanced Bladder Cancer: Is There a Role?. <i>European Urology Focus</i> , 2020 , 6, 615-616	5.1	2
195	AUTHOR REPLY. <i>Urology</i> , 2020 , 135, 65	1.6	
194	Reply to Siebren Dijkstra and Carl J. Wijnburg's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. <i>Eur Urol</i> 2018;74:465-71. Can the Pattern of Cancer Recurrence Truly be Assigned to the Surgical Modality?. <i>European Urology</i> , 2019 , 75, e138-e139	10.2	
193	A Thoughtful Pause for Sparing Oophorectomy. <i>Urology</i> , 2019 , 129, 237	1.6	
192	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. <i>Journal of Pathology</i> , 2019 , 248, 260-265	9.4	20
191	The Outcome of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Metastatic Bladder Cancer in the Retroperitoneum. <i>Bladder Cancer</i> , 2019 , 5, 13-19	1	4
190	Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy. <i>World Journal of Urology</i> , 2019 , 37, 2401-2407	4	2
189	Leveraging Latent Dirichlet Allocation in processing free-text personal goals among patients undergoing bladder cancer surgery. <i>Quality of Life Research</i> , 2019 , 28, 1441-1455	3.7	26
188	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 51-60	4	25
187	Evolution in technique of robotic intracorporeal continent catheterizable pouch after cystectomy. <i>Urology Video Journal</i> , 2019 , 4, 100020-100020	0.2	1

186	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies. <i>American Journal of Surgical Pathology</i> , 2019 , 43, 920-927	6.7	30
185	Update of the ICUD-SIU International Consultation on Bladder Cancer 2018: urinary diversion. <i>World Journal of Urology</i> , 2019 , 37, 85-93	4	14
184	Perceptions of Response Burden Associated with Completion of Patient-Reported Outcome Assessments in Oncology. <i>Value in Health</i> , 2019 , 22, 225-230	3.3	20
183	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019 , 51, 202-206	36.3	1435
182	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 967-976	12.9	94
181	Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. <i>European Urology</i> , 2019 , 75, 231-239	10.2	53
180	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. <i>European Urology Focus</i> , 2019 , 5, 201-204	5.1	18
179	The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. <i>European Urology Focus</i> , 2019 , 5, 104-108	5.1	36
178	Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. <i>European Urology Focus</i> , 2019 , 5, 365-368	5.1	9
177	Development and validation of surgical training tool: cystectomy assessment and surgical evaluation (CASE) for robot-assisted radical cystectomy for men. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018 , 32, 4458-4464	5.2	8
176	Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. <i>Cancer</i> , 2018 , 124, 2507-2514	6.4	7
175	Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy. <i>BJU International</i> , 2018 , 122, 627-632	5.6	14
174	Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018 , 36, 645-653	4	2
173	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 213-218	3.3	10
172	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. <i>Human Pathology</i> , 2018 , 77, 63-69	3.7	18
171	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). <i>European Urology</i> , 2018 , 74, 294-306	10.2	176
170	Male Neobladder. <i>Urologic Clinics of North America</i> , 2018 , 45, 37-48	2.9	2
169	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018 , 24, 1965-1973	12.9	51

168	Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	15
167	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1949-1956	2.2	72
166	Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device. <i>Urology</i> , 2018 , 122, 121-126	1.6	5
165	Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. <i>European Urology</i> , 2018 , 74, 465-471	10.2	114
164	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. <i>World Journal of Urology</i> , 2017 , 35, 327-335	4	23
163	Idiographic quality of life assessment before radical cystectomy. <i>Psycho-Oncology</i> , 2017 , 26, 206-213	3.9	5
162	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2017 , 23, 3610-3618	12.9	143
161	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017 , 23, 703-713	50.5	1638
160	Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. <i>Journal of Urology</i> , 2017 , 198, 552-559	2.5	362
159	Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin. <i>Cancer Cytopathology</i> , 2017 , 125, 416-426	3.9	20
158	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. <i>European Urology</i> , 2017 , 72, 952-959	10.2	168
157	Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma of the Bladder who failed Bacillus Calmette Guerin (NCT01259063). <i>Bladder Cancer</i> , 2017 , 3, 113-119	1	8
156	Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017 , 13, 621-625	3.1	27
155	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 ,	3.3	7
154	Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 603.e1-603.e5	2.8	9
153	Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-based Chemotherapy: A Single-arm, Multicenter, Phase 2 Trial. <i>European Urology</i> , 2017 , 71, 299-300	10.2	1
152	Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. <i>European Urology</i> , 2017 , 71, 545-557	10.2	46
151	A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. <i>Urology</i> , 2017 , 102, 164-172	1.6	29

150	Urinary Bladder 2017 , 765-773		8
149	Complications of Ileal Conduit Diversion 2017 , 63-79		2
148	Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2017 ,	3.3	14
147	Accuracy of Self-reported Smoking Exposure Among Bladder Cancer Patients Undergoing Surveillance at a Tertiary Referral Center. <i>European Urology Focus</i> , 2016 , 2, 441-444	5.1	3
146	Rationale and Early Experience with Prophylactic Placement of Mesh to Prevent Parastomal Hernia Formation after Ileal Conduit Urinary Diversion and Cystectomy for Bladder Cancer. <i>Current Urology Reports</i> , 2016 , 17, 9	2.9	22
145	Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs. <i>European Urology</i> , 2016 , 70, 176-187	10.2	167
144	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016 , 48, 356-8	36.3	111
143	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2016 , 195, 1684-1689	2.5	27
142	Parastomal hernias after radical cystectomy and ileal conduit diversion. <i>Investigative and Clinical Urology</i> , 2016 , 57, 240-8	1.9	17
141	A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. <i>Journal of Urology</i> , 2016 , 196, 1014-20	2.5	22
140	Genomic characterization of response to chemoradiation in urothelial bladder cancer. <i>Cancer</i> , 2016 , 122, 3715-3723	6.4	37
139	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. <i>European Urology</i> , 2015 , 68, 238-53	10.2	168
138	Quality of life and symptom assessment in randomized clinical trials of bladder cancer: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 331.e17-23	2.8	9
137	Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery?. <i>Urologic Clinics of North America</i> , 2015 , 42, 189-99, viii	2.9	7
136	Cost comparison of open and robotic partial nephrectomy using a short postoperative pathway. <i>Urology</i> , 2015 , 85, 596-603	1.6	22
135	Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015 , 68, 970-7	10.2	147
134	Intradiverticular bladder cancer: CT imaging features and their association with clinical outcomes. <i>Clinical Imaging</i> , 2015 , 39, 94-8	2.7	12
133	Comparison of perioperative outcomes for epidural versus intravenous patient-controlled analgesia after radical cystectomy. <i>Regional Anesthesia and Pain Medicine</i> , 2015 , 40, 239-44	3.4	21

132	Id Proteins Contribute to Tumor Development and Metastatic Colonization in a Model of Bladder Carcinogenesis. <i>Bladder Cancer</i> , 2015 , 1, 159-170	1	2
131	Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. <i>European Urology</i> , 2015 , 67, 1042-1050	10.2	337
130	Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. <i>European Urology</i> , 2015 , 67, 198-201	10.2	105
129	Re: whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. <i>European Urology</i> , 2015 , 67, 350-1	10.2	2
128	Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. <i>European Urology</i> , 2015 , 67, 363-75	10.2	128
127	The Role of Lymphadenectomy in the Management of Urothelial Carcinoma of the Upper Urinary Tract 2015 , 153-178		
126	The mechanism of action of BCG therapy for bladder cancer--a current perspective. <i>Nature Reviews Urology</i> , 2014 , 11, 153-62	5.5	384
125	More on robot-assisted laparoscopic radical cystectomy. <i>New England Journal of Medicine</i> , 2014 , 371, 1655	59.2	1
124	Aminopeptidase activities as prospective urinary biomarkers for bladder cancer. <i>Proteomics - Clinical Applications</i> , 2014 , 8, 317-26	3.1	9
123	Adherence to surveillance guidelines after radical cystectomy: a population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 779-84	2.8	9
122	Risk of fracture after radical cystectomy and urinary diversion for bladder cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3291-8	2.2	27
121	Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings. <i>International Urology and Nephrology</i> , 2014 , 46, 1699-705	2.3	27
120	Editorial comment. <i>Urology</i> , 2014 , 83, 861-2	1.6	
119	Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder. <i>Journal of Urology</i> , 2014 , 192, 702-7	2.5	50
118	The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 657-62	2.8	13
117	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 637-44	2.8	41
116	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. <i>Cancer Discovery</i> , 2014 , 4, 1140-53	24.4	361
115	Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. <i>Clinical Cancer Research</i> , 2014 , 20, 1873-83	12.9	38

114	A randomized trial of robot-assisted laparoscopic radical cystectomy. <i>New England Journal of Medicine</i> , 2014 , 371, 389-90	59.2	62
113	Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience. <i>International Scholarly Research Notices</i> , 2014 , 2014, 702653	0	10
112	Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. <i>Nature Reviews Urology</i> , 2014 , 11, 589-96	5.5	49
111	Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. <i>BJU International</i> , 2014 , 113, 11-23	5.6	198
110	Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. <i>Cancer Discovery</i> , 2014 , 4, 1014-21	24.4	98
109	Risk factors for the development of parastomal hernia after radical cystectomy. <i>Journal of Urology</i> , 2014 , 191, 1708-13	2.5	55
108	The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2014 , 32, 453-9	4	16
107	Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. <i>Cancer</i> , 2013 , 119, 143-9	6.4	27
106	Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. <i>BJU International</i> , 2013 , 111, 589-95	5.6	20
105	Urinary diversion practice patterns among certifying American urologists. <i>Journal of Urology</i> , 2013 , 189, 1042-7	2.5	12
104	Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3133-40	2.2	226
103	Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed for nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2013 , 190, 1187-91	2.5	24
102	ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate. <i>European Urology</i> , 2013 , 63, 81-7	10.2	20
101	A prospective study of quality of life in patients undergoing pelvic exenteration: interim results. <i>Gynecologic Oncology</i> , 2013 , 128, 191-7	4.9	34
100	Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 968-73	2.8	6
99	Lymphadenectomy for bladder cancer at the time of radical cystectomy. <i>European Urology</i> , 2013 , 64, 266-76	10.2	53
98	Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. <i>BJU International</i> , 2013 , 111, E325-30	5.6	61
97	Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure. <i>Journal of Urology</i> , 2013 , 190, 1686-91	2.5	35

96	Does minimally invasive surgery for radical cystectomy provide similar long-term cancer control as open radical surgery?. <i>Current Opinion in Urology</i> , 2013 , 23, 449-55	2.8	5
95	Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. <i>European Urology</i> , 2012 , 61, 1025-30	10.2	80
94	Pelvic exenteration with curative intent for recurrent uterine malignancies. <i>Gynecologic Oncology</i> , 2012 , 124, 42-7	4.9	52
93	Re: Pelvic exenteration with curative intent for recurrent uterine malignancies <i>Gynecologic Oncology</i> , 2012 , 126, 312-313	4.9	
92	A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. <i>European Urology</i> , 2012 , 62, 523-33	10.2	162
91	Genome sequencing identifies a basis for everolimus sensitivity. <i>Science</i> , 2012 , 338, 221	33.3	546
90	Pubovesical fistula: a rare complication after treatment of prostate cancer. <i>Urology</i> , 2012 , 80, 446-51	1.6	36
89	Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 1323-33	12.9	138
88	Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. <i>Molecular Imaging and Biology</i> , 2012 , 14, 245-51	3.8	42
87	Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. <i>BJU International</i> , 2012 , 109, 77-82	5.6	136
86	Muscle-Invasive Urothelial Carcinoma: Conventional and Variant Subtypes 2012 , 143-163		
85	A plea for a uniform surveillance schedule after radical cystectomy. <i>Journal of Urology</i> , 2011 , 185, 2091-6.5		16
84	Bladder cancer imaging: an update. <i>Current Opinion in Urology</i> , 2011 , 21, 393-7	2.8	8
83	Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy. <i>BJU International</i> , 2011 , 108, E272-7	5.6	8
82	The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. <i>European Urology</i> , 2011 , 60, 767-75	10.2	111
81	The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgery. <i>Health and Quality of Life Outcomes</i> , 2011 , 9, 10	3	24
80	Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. <i>Journal of Pathology</i> , 2011 , 224, 270-9	9.4	62
79	The effect of age and gender on bladder cancer: a critical review of the literature. <i>BJU International</i> , 2010 , 105, 300-8	5.6	193

78	Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma. <i>BJU International</i> , 2010 , 106, 1502-7	5.6	7
77	Clinical outcome of primary versus secondary bladder carcinoma in situ. <i>Journal of Urology</i> , 2010 , 184, 464-9	2.5	28
76	Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. <i>Journal of Urology</i> , 2010 , 184, 74-80	2.5	40
75	Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches. <i>Journal of Urology</i> , 2010 , 183, 862-69	2.5	60
74	Overview of SUO Winter 2008 proceedings. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010 , 28, 67-8	2.8	
73	Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. <i>Journal of Urology</i> , 2010 , 183, 1751-6	2.5	18
72	The effect of age on bladder cancer incidence, prognosis and therapy. <i>Aging Health</i> , 2010 , 6, 649-659		6
71	Words of wisdom. Re: Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. <i>European Urology</i> , 2010 , 57, 175	10.2	1
70	A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution?. <i>European Urology</i> , 2010 , 58, 374-83	10.2	40
69	Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. <i>European Urology</i> , 2010 , 58, 581-7	10.2	165
68	The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. <i>European Urology</i> , 2010 , 58, 574-80	10.2	129
67	Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique?. <i>European Urology</i> , 2010 , 58, 645-51	10.2	81
66	Bladder cancer: narrowing the gap between evidence and practice. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5680-4	2.2	47
65	Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. <i>European Urology</i> , 2009 , 55, 177-85	10.2	174
64	Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. <i>European Urology</i> , 2009 , 55, 164-74	10.2	889
63	Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. <i>European Urology</i> , 2009 , 56, 903-10	10.2	86
62	Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. <i>Cancer</i> , 2009 , 115, 5460-9	6.4	24
61	Optimal timing of radical cystectomy for patients with T1 bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 329-31	2.8	12

60	Ureteroileocecal appendicostomy based urinary reservoir in irradiated and nonirradiated patients. <i>Journal of Urology</i> , 2009 , 182, 2376-80	2.5	10
59	Identification of Nodal Metastases: The role of Iron Oxide Enhanced MRI 2009 , 67-77		
58	Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. <i>European Urology</i> , 2008 , 53, 370-5	10.2	78
57	Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance. <i>Journal of Urology</i> , 2008 , 179, 96-100	2.5	62
56	Gene therapy in bladder cancer. <i>Current Opinion in Urology</i> , 2008 , 18, 519-23	2.8	11
55	Bladder cancer: can imaging change patient management?. <i>Current Opinion in Urology</i> , 2008 , 18, 98-104	2.8	32
54	Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. <i>Cancer</i> , 2008 , 112, 2384-92	6.4	202
53	A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. <i>Cancer</i> , 2008 , 113, 2471-7	6.4	188
52	Urachal carcinoma: contemporary surgical outcomes. <i>Journal of Urology</i> , 2007 , 178, 74-8; discussion 78	2.5	103
51	Prognostic significance of p27Kip1 expression in bladder cancer. <i>BJU International</i> , 2007 , 100, 259-63	5.6	31
50	Evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancer. <i>International Journal of Urology</i> , 2007 , 14, 26-32	2.3	51
49	Radical cystectomy and lymphadenectomy for invasive bladder cancer: towards the evolution of an optimal surgical standard. <i>Seminars in Oncology</i> , 2007 , 34, 110-21	5.5	16
48	How prevalent is neobladder emptying failure, and how can it be treated?. <i>Nature Reviews Urology</i> , 2007 , 4, 364-5		
47	Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors. <i>Clinical Cancer Research</i> , 2007 , 13, 4511-8	12.9	23
46	Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. <i>Urologia Internationalis</i> , 2007 , 78, 160-6	1.9	19
45	Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. <i>Urology</i> , 2007 , 69, 255-9	1.6	62
44	The use and abuse of data: nomograms and talking to patients about clinical medicine. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 333-7	2.8	8
43	Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression. <i>American Journal of Pathology</i> , 2007 , 171, 1650-8	5.8	28

42	Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. <i>Journal of Urology</i> , 2007 , 177, 1283-6; discussion 1286	2.5	122
41	Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. <i>Cancer</i> , 2006 , 107, 506-13	6.4	270
40	Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer. <i>Cancer</i> , 2006 , 107, 2167-72	6.4	59
39	Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?. <i>Cancer</i> , 2006 , 107, 2368-74	6.4	178
38	Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3967-72	2.2	343
37	Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2729-34	2.2	143
36	Association between urinary cytology and pathology for nontransitional cell malignancies of the urinary tract. <i>Journal of Urology</i> , 2006 , 175, 2038-41; discussion 2041	2.5	8
35	Safety and efficacy of intravesical bacillus Calmette-Guérin instillations in steroid treated and immunocompromised patients. <i>Journal of Urology</i> , 2006 , 176, 482-5	2.5	41
34	Natural history of positive urinary cytology after radical cystectomy. <i>Journal of Urology</i> , 2006 , 176, 2000-5; discussion 2005	2.5	22
33	Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5519-27	2.2	79
32	Importance of node dissection in relation to neoadjuvant and adjuvant therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006 , 4, 1019-26	7.3	1
31	Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. <i>BJU International</i> , 2006 , 98, 59-62	5.6	39
30	Use of nomograms as predictive tools in bladder cancer. <i>World Journal of Urology</i> , 2006 , 24, 489-98	4	12
29	Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer?. <i>Journal of Urology</i> , 2005 , 173, 1513-7	2.5	57
28	Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. <i>Journal of Urology</i> , 2005 , 174, 741-6	2.5	25
27	Current status of establishing standards for lymphadenectomy in the treatment of bladder cancer. <i>Current Opinion in Urology</i> , 2005 , 15, 315-9	2.8	7
26	Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2005 , 99, 608-14	4.9	123
25	Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin. <i>Clinical Cancer Research</i> , 2004 , 10, 1835-42	12.9	30

24	Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. <i>Clinical Cancer Research</i> , 2004 , 10, 7457-65	12.9	186
23	Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation. <i>Gynecologic Oncology</i> , 2004 , 94, 140-6	4.9	11
22	Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. <i>Journal of Urology</i> , 2004 , 172, 878-81	2.5	121
21	Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. <i>Journal of Urology</i> , 2004 , 172, 1286-90	2.5	175
20	Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. <i>Journal of Urology</i> , 2004 , 172, 2177-81	2.5	72
19	Importance of lymph node dissection in urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004 , 22, 197	2.8	
18	274: Phase II Trial of Intra Vesical Gemcitabine in BCG-Refractory Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2004 , 171, 72-72	2.5	9
17	Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. <i>Urologic Clinics of North America</i> , 2003 , 30, 777-89	2.9	48
16	Detection and quantitative analysis of early stage orthotopic murine bladder tumor using in vivo magnetic resonance imaging. <i>Journal of Urology</i> , 2003 , 170, 1375-8	2.5	22
15	Orthotopic Urinary Diversion After Cystectomy For Bladder Cancer: Implications For Cancer Control And Patterns Of Disease Recurrence. <i>Journal of Urology</i> , 2003 , 169, 177-181	2.5	78
14	Umbilical endometriosis. <i>Journal of Urology</i> , 2003 , 170, 2388-9	2.5	11
13	Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. <i>Journal of Urology</i> , 2003 , 169, 177-81	2.5	23
12	International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3206-12	2.2	182
11	Tissue-specific transcriptional targeting of a replication-competent retroviral vector. <i>Journal of Virology</i> , 2002 , 76, 12783-91	6.6	44
10	IMPACT OF THE NUMBER OF LYMPH NODES RETRIEVED ON OUTCOME IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2002 , 167, 1295-1298	2.5	469
9	Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. <i>Journal of Urology</i> , 2002 , 167, 1295-8	2.5	115
8	Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. <i>Journal of Clinical Oncology</i> , 2001 , 19, 666-75	2.2	2619
7	Development of lentiviral vectors for antiangiogenic gene delivery. <i>Cancer Gene Therapy</i> , 2001 , 8, 879-89	3.4	52

6	IMPACT OF SEPARATE VERSUS EN BLOC PELVIC LYMPH NODE DISSECTION ON THE NUMBER OF LYMPH NODES RETRIEVED IN CYSTECTOMY SPECIMENS. <i>Journal of Urology</i> , 2001 , 166, 2295-2296	2.5	213
5	NOREPINEPHRINE PRODUCING RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2001 , 166, 603-603	2.5	
4	AN ALTERNATIVE URETEROILEAL REIMPLANTATION USED IN AUGMENTATION CYSTOPLASTY FOR NEUROGENIC BLADDER WITH BILATERAL VESICOURETERAL REFLUX. <i>Journal of Urology</i> , 1998 , 160, 1416-1417	2.5	0
3	SALVAGE RADICAL CYSTOPROSTATECTOMY AND ORTHOTOPIC URINARY DIVERSION FOLLOWING RADIATION FAILURE. <i>Journal of Urology</i> , 1998 , 160, 29-33	2.5	77
2	The T pouch: an orthotopic ileal neobladder incorporating a serosal lined ileal antireflux technique. <i>Journal of Urology</i> , 1998 , 159, 1836-42	2.5	112
1	Role of extended lymphadenectomy176-183		